COVID-19在人体内进化
COVID-19 Evolves in Human Hosts
摘要：
今天，我们都受到前所未有的大流行病的威胁：COVID-19。它与其他冠状病毒有何不同？它会变弱还是变得更毒？哪些动物可能是它的原始宿主？在这项研究中，我们收集并分析了来自79个不同国家的近3万个公开可用的COVID-19病毒的完整基因组序列，包括先前已知的流感引起的冠状病毒（HCov-229 E，HCov-OC 43，HCov-NL 63和HCov-HKU 1）以及致命的致病病毒SARS，MERS，维多利亚，拉萨，山形，埃博拉和登革热。我们发现目前流行的COVID-19与SARS和MERS之间存在很强的相似性，以及COVID-19在马索拉非尼和穿山甲中的相似性。相反，COVID-19与引起流感的冠状病毒和其他已知病毒几乎没有相似之处。值得注意的是，我们观察到从人类宿主分离的COVID-19菌株的差异从2019年12月至2020年5月稳步增加，表明COVID-19正在人类宿主中积极进化。本文首先提出了一种用于大序列分析的MLCS算法NP-MLCS 1，该算法可以计算COVID-19全基因组序列的通用模型，为疫苗和抗体开发提供重要信息。对人类COVID-19进化树的地理和时间过程分析揭示了来自79个国家的菌株之间可能的进化路径。这一发现对COVID-19的管理以及疫苗和药物的开发具有重要意义。
英文摘要：
Today, we are all threatened by an unprecedented pandemic: COVID-19. How different is it from other coronaviruses? Will it be attenuated or become more virulent? Which animals may be its original host? In this study, we collected and analyzed nearly thirty thousand publicly available complete genome sequences for COVID-19 virus from 79 different countries, the previously known flu-causing coronaviruses (HCov-229E, HCov-OC43, HCov-NL63 and HCov-HKU1) and the lethal, pathogenic viruses, SARS, MERS, Victoria, Lassa, Yamagata, Ebola, and Dengue. We found strong similarities between the current circulating COVID-19 and SARS and MERS, as well as COVID-19 in rhinolophines and pangolins. On the contrary, COVID-19 shares little similarity with the flu-causing coronaviruses and the other known viruses. Strikingly, we observed that the divergence of COVID-19 strains isolated from human hosts has steadily increased from December 2019 to May 2020, suggesting COVID-19 is actively evolving in human hosts. In this paper, we first propose a novel MLCS algorithm NP-MLCS1 for the big sequence analysis, which can calculate the common model for COVID-19 complete genome sequences to provide important information for vaccine and antibody development. Geographic and time-course analysis of the evolution trees of the human COVID-19 reveals possible evolutional paths among strains from 79 countries. This finding has important implications to the management of COVID-19 and the development of vaccines and medications.
机构、总结、中文摘要均由AI分析而来，可能存在错误，请以论文正文为准。
